Drugs / Firsocostat
Firsocostat
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02891408 | Sep 2016 → May 2019 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02876796 | Aug → Sep 2015 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT04971785 | Aug 2021 → Nov 2024 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03987074 | Jul 2019 → Jul 2020 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03449446 | Mar 2018 → Oct 2019 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02856555 | Aug 2016 → Jul 2017 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02781584 | Jun 2016 → Dec 2020 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-10-24 | Gilead Sciences | Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) gilead.com ↗ |
| 2017-04-21 | Gilead Sciences | Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017 gilead.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Firsocostat | “the acetyl-CoA carboxylase inhibitor firsocostat (FIR) improved liver histology and biomarkers in NASH with advanced fibrosis” PMID 34999207 ↗ Jan 2022 |
| Known as | FIR | “the acetyl-CoA carboxylase inhibitor firsocostat (FIR) improved liver histology and biomarkers in NASH with advanced fibrosis” PMID 34999207 ↗ Jan 2022 |
| Known as | GS-0976 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876796 ↗ |
| Known as | GS-ACC | ChEMBL registry synonym — accepted as the source's own label CHEMBL3407547 ↗ |
| Known as | ND-630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3407547 ↗ |
| Known as | Ndi-010976 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3407547 ↗ |
| Action | Inhibit | “the acetyl-CoA carboxylase inhibitor firsocostat (FIR)” PMID 34999207 ↗ Jan 2022 |
| Modality | Small molecule | — CHEMBL3407547 ↗ |
| Route | Oral | “Administered orally once daily” NCT02781584 ↗ |